Doug is President, CEO, and Co-Founder of Seventh Sense Biosystems. He is also a Partner at Flagship Ventures, where he co-founded and served as Founding CEO of T2 Biosystems. Prior to Flagship, Dr. Levinson was with TransForm Pharmaceuticals as part of its scientific founding-team, along with Professor Bob Langer. As V.P. of Emerging Science and Technology, he led the design, development, and implementation of TransForm's basic technology platforms and business model, for which it was acquired by Johnson & Johnson. Prior to TransForm, Dr. Levinson was a founding scientific team member with Millennium Pharmaceuticals where he established the company's early scientific program in Immunology/Inflammation, which he grew to the largest research effort at the company. Dr. Levinson holds a Ph.D. in genetics from Harvard University and is an inventor on 19 issued patents in the life sciences.
Howard is Chief Scientific Officer at Seventh Sense Biosystems. Dr. Bernstein has over 20 years of experience in microparticle/nanoparticle technology and drug development. He has been involved in the development of five different nanoparticulate and microparticulate products including Nutropin Depot, which was the first sustained release product to be approved by the FDA. Before joining Seventh Sense, Dr. Bernstein was Executive Vice President of Research and Development at Acusphere, Inc. and prior to that, he was Vice President of Pharmaceutical Development at Alkermes. He holds 50 US patents and patent applications. Dr. Bernstein received his Ph.D. in chemical engineering from MIT and his M.D. from Harvard Medical School through the MIT-Harvard Health Sciences and Technology program.
Don is Vice President of Engineering at Seventh Sense Biosystems. Before joining Seventh Sense, Dr. Chickering was Vice President of Technical Operations at Acusphere, Inc. Prior to that, he was Project Leader of the Therapeutic Delivery Systems group at Sulzer/Carbomedics. He has a total of 14 years experience in the areas of medical devices, microparticles, and drug delivery systems, and he holds 30 US patents in these fields. Dr. Chickering was the recipient of the American Association of Medical Instrumentation Young Investigator Award and the Boston Business Journal's 40 Under 40 Award. He also served on the Northeastern University Industrial Advisory Board for the Chemical Engineering Department. Dr. Chickering has a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute and received his Ph.D. from Brown University's Department of Molecular Pharmacology and Biotechnology.
Christopher is Director of Corporate Development at Seventh Sense Biosystems. Before joining Seventh Sense, Mr. McNulty was Associate Director of Business Development and Alliance Management at Genzyme, where he was a key member of the business development teams for large collaborations with Isis Pharmaceuticals, Inc. and PTC Therapeutics, Inc. After helping to close both deals, he was responsible for alliance and program management with both Isis and PTC. Prior to Genzyme, Mr. McNulty was the Director of Informatics at Transform Pharmaceuticals, where he led a team of 20 scientists, engineers, and developers. Mr. McNulty also worked at Cereon Genomics in the area of expression profiling and at Hewlett Packard Labs in the area of noninvasive glucose monitoring. Mr. McNulty received B.S. and M.Eng. degrees from MIT in electrical engineering and computer science and an M.B.A. from Harvard Business School.